Emily Cheng

Osteotropic nanoscale drug delivery systems based on small molecule bone-targeting moieties.

K. W. Lo, Erica J. Carbone, B. Ulery, 2017, Nanomedicine : nanotechnology, biology, and medicine.

The TWEAK Receptor Fn14 is a Novel Therapeutic Target in Melanoma: Immunotoxins Targeting Fn14 Receptor for Malignant Melanoma Treatment

W. Hittelman, M. Rosenblum, N. Tran, 2012, The Journal of investigative dermatology.

Interleukin-12 as an in situ cancer vaccine component: a review

A. Rakhmilevich, P. Sondel, Emily Cheng, 2022, Cancer Immunology, Immunotherapy.

TWEAK/Fn14 Axis-Targeted Therapeutics: Moving Basic Science Discoveries to the Clinic

J. Winkles, Emily Cheng, R. Galisteo, 2013, Front. Immunol..

Elevated expression of Fn14 in non-small cell lung cancer correlates with activated EGFR and promotes tumor cell migration and invasion.

C. Kingsley, G. Hostetter, G. Weiss, 2012, The American journal of pathology.

Minimizing the non-specific binding of nanoparticles to the brain enables active targeting of Fn14-positive glioblastoma cells.

A. Kim, J. Winkles, G. Woodworth, 2015, Biomaterials.

The TWEAK Receptor Fn14 Is an Src-Inducible Protein and a Positive Regulator of Src-Driven Cell Invasion

N. Tran, J. Winkles, T. Whitsett, 2014, Molecular Cancer Research.

TWEAK-Independent Fn14 Self-Association and NF-κB Activation Is Mediated by the C-Terminal Region of the Fn14 Cytoplasmic Domain

J. Winkles, Mark S Williams, Emily Cheng, 2013, PloS one.